GENE Genetic Technologies Ltd featured news, full reports, and detailed charts
Genetic Technologies Ltd (GENE) Wrap Up:
We were incorporated under the laws of Western Australia on January 5, 1987 as Concord Mining N.L. On August 13, 1991 we changed our name to Consolidated Victorian Gold Mines N.L. On December 2, 1991, we changed our name to Consolidated Victorian Mines N.L. On March 15, 1995, we changed our name to Duketon Goldfields N.L. On October 15, 1999, the type of company was changed from a No Liability Company to a company limited by shares. On August 29, 2000, we changed our name to Genetic Technologies Limited, which is our current name. We were originally incorporated as a mining company and gradually phased out our mining activities and became a biotechnology company with the acquisition of GeneType AG in August 2000. Our Australian Company Number (ACN) is 009 212 328. Our Australian Business Number (ABN) is 17 009 212 328. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f12%2f20%2f0001104659-07-090063.html#FIS_COMPANY_INFORMATION"Genetic Technologies Ltd (GENE:NASDAQ)
Snapshot of Genetic Technologies Ltd (GENE)
|
OPEN
$1.43
|
PREVIOUS CLOSE
$1.32
|
|
|
DAY HIGH
$1.43
|
DAY LOW
$1.30
|
|
|
52 WEEK HIGH
04/27/09 - $4.99
|
52 WEEK LOW
03/10/09 - $0.80
|
|
|
MARKET CAP
16.3M
|
AVERAGE VOLUME 3 mo
3.2K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
12.5M
|
|
|
GENE Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
GENE Top Compensated Officers
Executives, Board Directors
Key developments for Genetic Technologies Ltd (GENE)
Rosetta Genomics Ltd. and Genetic Technologies Ltd. announced the signing of an exclusive distribution agreement for Rosetta Genomics' three currently available diagnostic tests. Under the terms of the agreement, GTG will market Rosetta Genomics' miRview(TM) tests in Australia, New Zealand and Singapore. Further financial terms were not disclosed. The following tests will be distributed by Genetic Technologies, miRview(TM) mets. This test can accurately identify the primary tumor site in patients presenting with metastatic cancer, as well in patients whose tumor has not been identified, and consequently been labeled Cancer of Unknown Primary (CUP). miRview(TM) squamous Using a single microRNA, miRview(TM) squamous differentiates squamous from non-squamous, non-small cell lung cancer (NSCLC) patients. miRview(TM) meso. This test leverages microRNA's high specificity as biomarkers to differentiate mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung.
Genetic Technologies Ltd., Annual General Meeting, Nov 25, 2009, at 10:00 EAST-East Australian Standard GST. Location: `Treetops' Melbourne Museum, 11 Nicholson Street, Carlton, Victoria 3053, Australia. Agenda: To receive and consider the financial report, directors' report and auditor's report for the year ended 30 June 2009; to consider and, if thought fit, to pass the resolution as an ordinary resolution that to re-elect Mr. Fred Bart, Mr. Sidney Charles Hack, Mr. Huw David Jones and Dr. Malcolm Roy Brandon as director; to adopt the remuneration report section of the directors' report for the company for the year ended 30 June 2009; and to accept the resignation of Ernst & Young as the existing auditor of the company by the date of the Annual General Meeting, PricewaterhouseCoopers, who has consented in writing to act as auditor of the company, be appointed as auditor of the company.
Genetic Technologies Ltd. appointed Dr. Malcolm Brandon as a non-executive Director of the Company. Dr. Brandon was co-founder and Director of Stem Cell Sciences Ltd. and Smart Drug Systems Inc. and is currently the Managing Director of genetics and artificial animal breeding company Clone International.
GENE Competitors
| Company | Last | Change |
| Genelink Inc | $0.16 USD | +0.01 |
| Genzyme Corp | $50.05 USD | +0.42 |
| Sonic Healthcare Ltd | A$14.02 AUD | -0.18 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | GENE | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 4.3x |
|
| Price/Book | 1.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 2.9x |
|
|
GENE |
||
GENE transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Genetic Technologies Ltd
More news for GENE
GENETIC TECHNOLOGIES LTD Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)